Persistence of bactericidal antibodies following early infant vaccination with a serogroup B meningococcal vaccine and immunogenicity of a preschool booster dose

Persistence of bactericidal antibodies following early infant vaccination with a serogroup B meningococcal vaccine and immunogenicity of a preschool booster dose

Show other versions (1)

<p style="text-align:justify;"><b>Background:</b> The multicomponent serogroup B meningococcal (4CMenB) vaccine was recently licensed for use in Europe. There are currently no data on the persistence of bactericidal antibodies induced by use of this vaccine in infants. O...

Full description

Bibliographic Details
Main Authors:	Snape, M, Saroey, P, John, T, Robinson, H, Kelly, S, Gossger, N, Yu, L, Wang, H, Toneatto, D, Dull, P, Pollard, A
Format:	Journal article
Language:	English
Published:	Canadian Medical Association 2013

Similar Items

Persistence of bactericidal antibodies following early infant vaccination with a serogroup B meningococcal vaccine and immunogenicity of a preschool booster dose.
by: Snape, MD, et al.
Published: (2013)

Bactericidal antibody persistence 2 years after immunization with 2 investigational serogroup B meningococcal vaccines at 6, 8 and 12 months and immunogenicity of preschool booster doses: a follow-on study to a randomized clinical trial.
by: Snape, MD, et al.
Published: (2013)

Bactericidal antibody persistence 2 years after immunization with 2 investigational serogroup B meningococcal vaccines at 6, 8 and 12 months and immunogenicity of preschool booster doses: A follow-on study to a randomized clinical trial
by: Snape, MD, et al.
Published: (2013)

Will booster doses be required for serogroup B meningococcal vaccine?
by: McQuaid, F, et al.
Published: (2014)

Persistence of bactericidal antibodies following infant serogroup B meningococcal immunization (4CMenB) and booster dose response at 12, 18 or 24 months of age
by: Snape, M, et al.
Published: (2015)

Persistence of bactericidal antibodies to 5 years of age after immunization with serogroup B meningococcal vaccines at 6, 8, 12 and 40 months of age.
by: McQuaid, F, et al.
Published: (2014)

Serogroup C meningococcal glycoconjugate vaccine in adolescents: persistence of bactericidal antibodies and kinetics of the immune response to a booster vaccine more than 3 years after immunization.
by: Snape, MD, et al.
Published: (2006)

Serogroup c meningococcal glycoconjugate vaccine in adolescents: persistence of bactericidal antibodies and kinetics of the immune response to a booster vaccine more than 3 years after immunization
by: Snape, M, et al.
Published: (2006)

Immunogenicity and tolerability of recombinant serogroup B meningococcal vaccine administered with or without routine infant vaccinations according to different immunization schedules: a randomized controlled trial.
by: Gossger, N, et al.
Published: (2012)

Persistence of specific bactericidal antibodies at 5 years of age after vaccination against serogroup B meningococcus in infancy and at 40 months.
by: McQuaid, F, et al.
Published: (2015)

Lack of serum bactericidal activity in preschool children two years after a single dose of serogroup C meningococcal polysaccharide-protein conjugate vaccine.
by: Snape, MD, et al.
Published: (2005)

Long-term seroprotection after an adolescent booster meningococcal serogroup C vaccination.
by: de Whalley, P, et al.
Published: (2013)

Long-term seroprotection after an adolescent booster meningococcal serogroup C vaccination
by: De Whalley, P, et al.
Published: (2013)

Immunogenicity of reduced dose priming schedules of serogroup C meningococcal conjugate vaccine followed by booster at 12 months in infants: open label randomised controlled trial.
by: Pace, D, et al.
Published: (2015)

Adolescents need a booster of serogroup C meningococcal vaccine to protect them and maintain population control of the disease.
by: Pollard, A, et al.
Published: (2013)

Immunogenicity and immune memory of a nonadjuvanted quadrivalent meningococcal glycoconjugate vaccine in infants.
by: Perrett, K, et al.
Published: (2009)

Immunogenicity of two investigational serogroup B meningococcal vaccines in the first year of life: a randomized comparative trial.
by: Snape, MD, et al.
Published: (2010)

Immunogenicity of a tetravalent meningococcal glycoconjugate vaccine in infants: a randomized controlled trial.
by: Snape, MD, et al.
Published: (2008)

Baseline polysaccharide-specific antibodies may not consistently inhibit booster antibody responses in infants to a serogroup C meningococcal protein-polysaccharide conjugate vaccine
by: Blanchard-Rohner, G, et al.
Published: (2012)

Baseline polysaccharide-specific antibodies may not consistently inhibit booster antibody responses in infants to a serogroup C meningococcal protein-polysaccharide conjugate vaccine.
by: Blanchard-Rohner, G, et al.
Published: (2012)

Serogroup B meningococcal vaccines-an unfinished story.
by: Sadarangani, M, et al.
Published: (2010)

Immunologic memory with no detectable bactericidal antibody response to a first dose of meningococcal serogroup C conjugate vaccine at four years.
by: McVernon, J, et al.
Published: (2003)

Persistence of immunity following a booster dose of Haemophilus influenzae type B-Meningococcal serogroup C glycoconjugate vaccine: follow-up of a randomized controlled trial.
by: Khatami, A, et al.
Published: (2011)

Persistence of bactericidal antibodies following booster vaccination with 4CMenB at 12, 18 or 24months and immunogenicity of a fifth dose administered at 4years of age-a phase 3 extension to a randomised controlled trial.
by: Iro, M, et al.
Published: (2016)

Corrigendum to "Persistence of bactericidal antibodies following booster vaccination with 4CMenB at 12, 18 or 24months and immunogenicity of a fifth dose administered at 4years of age-a phase 3 extension to a randomised controlled trial" [Vaccine 35 (2017) 395-402].
by: Iro, M, et al.
Published: (2017)

Persistence of serum bactericidal antibody one year after a booster dose of either a glycoconjugate or a plain polysaccharide vaccine against serogroup C neisseria meningitidis given to adolescents previously immunized with a glycoconjugate vaccine
by: De Whalley, P, et al.
Published: (2011)

Persistence of serum bactericidal antibody one year after a booster dose of either a glycoconjugate or a plain polysaccharide vaccine against serogroup C Neisseria meningitidis given to adolescents previously immunized with a glycoconjugate vaccine.
by: de Whalley, P, et al.
Published: (2011)

Demonstration of immunologic memory using serogroup C meningococcal glycoconjugate vaccine.
by: Snape, MD, et al.
Published: (2009)

Exonic single nucleotide polymorphisms within TLR3 associated with infant responses to serogroup C meningococcal conjugate vaccine
by: O'Connor, D, et al.
Published: (2014)

Exonic single nucleotide polymorphisms within TLR3 associated with infant responses to serogroup C meningococcal conjugate vaccine.
by: O'Connor, D, et al.
Published: (2014)

Immunogenicity and immunologic memory of meningococcal C conjugate vaccine in premature infants.
by: Collins, C, et al.
Published: (2005)

Challenges and progress in the development of a serogroup B meningococcal vaccine.
by: Lewis, S, et al.
Published: (2009)

Meningococcal B vaccine immunogenicity in children with defects in complement and splenic function
by: Martinón-Torres, FL, et al.
Published: (2018)

Emergence of serogroup X meningococcal disease in Africa: need for a vaccine.
by: Xie, O, et al.
Published: (2013)

No evidence for capsule replacement following mass immunisation with meningococcal serogroup C conjugate vaccines in England and Wales - Authors' reply
by: Snape, MD, et al.
Published: (2006)

Single nucleotide polymorphisms in the Toll-like receptor 3 and CD44 genes are associated with persistence of vaccine-induced immunity to the serogroup C meningococcal conjugate vaccine.
by: Moore, C, et al.
Published: (2012)

Persistence of immunity after vaccination with a capsular group B meningococcal vaccine in 3 different toddler schedules
by: Sadarangani, M, et al.
Published: (2017)

Meningococcal polysaccharide-protein conjugate vaccines.
by: Snape, MD, et al.
Published: (2005)

Use of a booster dose of capsular group C meningococcal glycoconjugate vaccine to demonstrate immunologic memory in children primed with one or two vaccine doses in infancy
by: Pace, D, et al.
Published: (2016)

A randomized trial assessing the immunogenicity and reactogenicity of two hexavalent infant vaccines concomitantly administered with group b meningococcal vaccine
by: Rajan, M, et al.
Published: (2022)